Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives

Francesco Facchinetti, Paola Bordi, Alessandro Leonetti, Sebastiano Buti, Marcello Tiseo Medical Oncology Unit, University Hospital of Parma, Parma, Italy Abstract: Programed cell death-1/programed death ligand-1 (PD-1/PD-L1) blockade represents an affirmed reality in the treatment of advanced non-s...

Full description

Saved in:

Bibliographic Details
Main Authors:	Facchinetti F (Author), Bordi P (Author), Leonetti A (Author), Buti S (Author), Tiseo M (Author)
Format:	Book
Published:	Dove Medical Press, 2018-09-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Effectiveness and safety of atezolizumab, nivolumab and pembrolizumab in metastatic non-small cell lung cancer
by: Amparo Burgos-San José, et al.
Published: (2021)

Non-small-cell lung cancer: how to manage BRAF-mutated disease
by: Giorgia Guaitoli, et al.
Published: (2023)

Atezolizumab-Induced Bell's Palsy in a Patient With Small Cell Lung Cancer
by: Asim Kichloo MD, et al.
Published: (2020)

Effectiveness and Cost-Effectiveness Profile of Second-Line Treatments with Nivolumab, Pembrolizumab and Atezolizumab in Patients with Advanced Non-Small Cell Lung Cancer
by: Matteo Franchi, et al.
Published: (2022)

Atezolizumab-Induced Stevens-Johnson Syndrome in a Patient with Non-Small Cell Lung Carcinoma
by: Phatcharawat Chirasuthat, et al.
Published: (2018)

Comparison of two‐stage and joint TGI‐OS modeling using data from six atezolizumab clinical studies in patients with metastatic non‐small cell lung cancer
by: Antonio Gonçalves, et al.
Published: (2024)

Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
by: Miriam Alonso-García, et al.
Published: (2022)

Economic Evaluation of First-Line Atezolizumab for Extensive-Stage Small-Cell Lung Cancer in the US
by: Yingcheng Wang, et al.
Published: (2021)

Cisplatin or carboplatin in the treatment of non-small cell lung cancer: a comprehensive review
by: Marcello Tiseo, et al.
Published: (2011)

Cisplatin or carboplatin in the treatment of non-small cell lung cancer: a comprehensive review
by: Marcello Tiseo, et al.
Published: (2011)

Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC)
by: M Tiseo, et al.
Published: (2010)

Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives
by: Lavacchi D, et al.
Published: (2019)

Atezolizumab-Induced Acrodermatitis and Pustular Psoriasis in a Patient with Non-Small Cell Lung Cancer: A Rare Case Report
by: Davide Fattore, et al.
Published: (2024)

Liquid Biopsy for Biomarker Testing in Non-Small Cell Lung Cancer: A European Perspective
by: Umberto Malapelle, et al.
Published: (2021)

Cost-Effectiveness of First-Line Atezolizumab versus Chemotherapy in Non-Small-Cell Lung Cancer Patients Ineligible for Platinum-Containing Regimens
by: Li LF, et al.
Published: (2024)

Tumor Time‐Course Predicts Overall Survival in Non‐Small Cell Lung Cancer Patients Treated with Atezolizumab: Dependency on Follow‐Up Time
by: Ida Netterberg, et al.
Published: (2020)

Cost-effectiveness analysis of atezolizumab in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen: a United Kingdom health care perspective
by: Yunlin Jiang, et al.
Published: (2023)

The Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine
by: Barbara Melosky
Published: (2015)

Genomic Landscape of Metastatic Lymph Nodes and Primary Tumors in Non-Small-Cell Lung Cancer
by: Bing Chen, et al.
Published: (2022)

Comparative analysis of using atezolizumab vs. durvalumab in combination with platinum-containing chemotherapy in adult patients with advanced small cell lung cancer
by: I. S. Krysanov, et al.
Published: (2023)

Metastatic squamous cell non-small-cell lung cancer (NSCLC): disrupting the drug treatment paradigm with immunotherapies
by: Sarah L Scarpace
Published: (2015)

Development and Evaluation of a Quantitative Systems Pharmacology Model for Mechanism Interpretation and Efficacy Prediction of Atezolizumab in Combination with Carboplatin and Nab-Paclitaxel in Patients with Non-Small-Cell Lung Cancer
by: Chen-Yu Wang, et al.
Published: (2024)

Current Insights on the Treatment of Anaplastic Lymphoma Kinase-Positive Metastatic Non-Small Cell Lung Cancer: Focus on Brigatinib
by: Rijavec E, et al.
Published: (2022)

Update on the Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine
by: Barbara Melosky
Published: (2018)

Brigatinib for ALK-positive metastatic non-small-cell lung cancer: design, development and place in therapy
by: Ali R, et al.
Published: (2019)

Predictive markers of response to immune checkpoint inhibitor rechallenge in metastatic non-small cell lung cancer
by: Aram A. Musaelyan, et al.
Published: (2024)

Metastatic Non-Small-Cell Lung Cancer Presenting as Renal Failure From IgA Nephropathy
by: Samer Yassin MD, et al.
Published: (2024)

Cost-effectiveness analysis of the tislelizumab versus docetaxel for advanced or metastatic non-small-cell lung cancer in China
by: Xiaoyu Zhang, et al.
Published: (2024)

Personalized treatment options for ALK-positive metastatic non-small-cell lung cancer: potential role for Ceritinib
by: El-Osta H, et al.
Published: (2015)

The Cost-Effectiveness of Tislelizumab Plus Chemotherapy for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer
by: Xia Luo, et al.
Published: (2022)

Atezolizumab plus carboplatin and nab‐paclitaxel versus carboplatin and nab‐paclitaxel as treatments for Chinese, treatment‐naïve, stage IV, non‐squamous, non‐small‐cell lung cancer patients: A retrospective analysis
by: Yingkai Chen, et al.
Published: (2022)

Pharmacoeconomic analysis of atezolizumab plus nab-paclitaxel in the treatment of the advanced or metastatic triple-negative breast cancer
by: A S Kolbin, et al.
Published: (2020)

Sugemalimab plus chemotherapy vs. chemotherapy for metastatic non-small-cell lung cancer: A cost-effectiveness analysis
by: Xueyan Liang, et al.
Published: (2023)

Cost-effectiveness analysis of Tumor Treating Fields treatment in Chinese patients with metastatic non-small cell lung cancer
by: Zhengda Pei, et al.
Published: (2024)

Modern Challenges for Early-Phase Clinical Trial Design and Biomarker Discovery in Metastatic Non-Small-Cell Lung Cancer
by: Antonio Rossi, et al.
Published: (2021)

Effect of the patient information brochure in communicating the risks associated with crizotinib treatment to patients with non‐small cell lung cancer (NSCLC) in Europe
by: Kui Huang, et al.
Published: (2020)

Sister Mary Joseph's nodule in a patient with metastatic small cell lung cancer
by: Sushil Ghimire, et al.
Published: (2015)

Cost-effectiveness of durvalumab plus tremelimumab in combination with chemotherapy for the treatment of metastatic non-small-cell lung cancer from the US healthcare sector's and societal perspectives
by: Yena Gan, et al.
Published: (2024)

Molecular profiling and prognostic biomarkers in chinese non-small cell lung cancer cohort
by: Fangfang Shen, et al.
Published: (2023)

The reimbursement process in three national healthcare systems: variation in time to reimbursement of pembrolizumab for metastatic non-small cell lung cancer
by: Sarah Sharman Moser, et al.
Published: (2023)